during recruitment of the patients and controls of this study, the conclusion of this trial might be not reasonable.
It has been reported that the prevalence of Hp-I in the city of Shiraz, where the study by Asadi-Pooya et al. was conducted, is very high, 2,3 regardless of the socioeconomic status, an already established significant factor affecting Hp prevalence in the European countries. This means that to prove a difference in Hp prevalence between any two groups in Shiraz would require several hundreds or even a few thousands of participants. Instead, Asadi-Pooya et al. presented their results based on a small number of patients and controls (34 and 33, respectively) and therefore the power of their study was too low. Specifically, the study groups were not age-matched. It seems that the control group was about 10 years older than the idiopathic generalized epilepsy (IGE) group and 2-3 years older than the temporal lobe epilepsy (TLE) group. Hp prevalence is higher in older individuals, and this explains why Hp-I was detected in 72.7% in the control group compared with 61.8% in the IGE and 50% of the TLE group. These differences did not reach a statistical significance due to the very small number of patients recruited, but it is almost certain that the p value equal to 0.068 reported would have been significant if the authors had recruited just a few more patients. In that case the control healthy group would have a higher Hp prevalence than the epileptic patients, leading to the paradox conclusion that Hp might protect against epilepsy.
On the other hand, recent data suggest a probable association between Hp-I and epilepsy, especially with poor prognosis. 4 In this respect, we speculate that Hp-I, by inducing proinflammatory cytokine production and blood-brain barrier (BBB) disruption, 5 also mentioned by the aurhors, 1 may lead to neuroinflammation and neuronal damage in epilepsy thereby triggering seizures' induction and epilepsy progression. 
